Impact of depression on treatment effectiveness and gains maintenance in social phobia: A naturalistic study of cognitive behavior group therapy

Depression and Anxiety

Volumn 26, Issue 3, 2009, Pages 289-300

  Marom, Sofi ^a,c   Gilboa Schechtman, Eva ^b   Aderka, Idan M ^b   Weizman, Abraham ^a   Hermesh, Haggai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Co morbidity; Cognitive behavioral therapy; Depression; Social phobia; Treatment outcome

Indexed keywords

ADULT; ARTICLE; COGNITIVE THERAPY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SOCIAL PHOBIA; STRUCTURED INTERVIEW; TREATMENT RESPONSE;

ADULT; COGNITIVE THERAPY; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; PHOBIC DISORDERS; PSYCHOTHERAPY, GROUP; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 63849233209     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20390     Document Type: Article

References (62)

1. Furmark T. Social phobia: overview of community surveys. Acta Psychiatr Scand 2002;105:84-93.
2. ChartierMJ, Walker JR, Stein MB. Considering comorbidity in social phobia. Soc Psychiatry Psychiatr Epidemiol 2003; 38:728-734.
3. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998;155: 613-619.
4. deWit DJ, Ogborne A, Offord DR, MacDonald K. Antecedents of the risk of recovery from DSM-III-R social phobia. Psychol Med 1999;29:569-582.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
6. Blanco C. Evidence-based pharmacotherapy of social anxiety disorder. CNS Spectr 2005;10:10-11.
7. Radomsky AS, Otto MW. Cognitive behavioral therapy for social anxiety disorder. The Psychiatr Clin N Am 2001;24:805-815.
8. Heimberg RG, Becker RE. Treatment of social fears and phobias. New York: Guilford Press; 2002.
9. Hofmann SG, Bogels SM. Recent advances in the treatment of social phobia: introduction to the special issue. J Cogn Psychother 2006;20:3-5.
10. Turk CL, Heimberg RG, Hope DA. Social anxiety disorder. In: Barlow DH, editor. Clinical handbook of psychological disorders, 3rd ed. New York: The Guilford Press; 2001.
11. Blomhoff S, Haug TT, Helstriöm K, Holme I, Humble M, Madsbu HP, Wold JE. Randomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry 2001;179:23-30.
12. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton Js, Zhao N, Connor KM, Lynch TR, Gadde KM. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-1013.
13. Gaston JE, Abbott MJ, Rapee RM, Neary SA. Do empirically supported treatments generalize to private practice? A benchmark study of a cognitive-behavioural group treatment programme for social phobia. Br J Clin Psychol 2006;45:33-48.
14. Lincoln TM, Rief W, Hahlweg K, Frank M, von Witzleben I, Schroeder B, Fiegenbaum W. Effectiveness of an empirically supported treatment for social phobia in the field. Behav Res Ther 2003;41:1251-1269.
15. Chambless DL, Tran GQ, Glass CR. Predictors of response to cognitive-behavioral group therapy for social phobia. J Anxiety Disord 1997;11:221-240.
16. Hope DA, Herbert JD, White C. Diagnostic subtype, avoidant personality disorder, and efficacy of cognitive behavioral group therapy for social phobia. Cogn Ther Res 1995;19: 399-417.
17. Turner SM, Beidel DC, Wolff PL, Spaulding S, Jacob RG. Clinical features affecting treatment outcome in social phobia. Behav Res Ther 1996;34:795-804.
18. Brown EJ, Heimberg RG, Juster HR. Social phobia subtype and avoidant personality disorder: effect on severity of social phobia, impairment, and outcome of cognitive-behavioral treatment. Behav Ther 1995;26:467-486.
19. Erwin BA, Heimberg RG, Juster H, Mindlin M. Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav Res Ther 2002;40:19-35.
20. Joormann J, Kosfelder J, Schulte D. The impact of comorbidity of depression on the course of anxiety treatments. Cogn Ther Res 2005;29:569-591.
21. Ledley DR, Huppert JD, Foa EB, Davidson JRT, Keefe FJ, Potts NLS. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depress Anxiety 2005;22:161-167.
22. Scholing A, Emmelkamp PMG. Prediction of treatment outcome in social phobia: a replication. Behav Res Ther 1999; 37:659-670.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20):22-33.
24. Heimberg RG, Juster HR, Hope DA, Mattia JI. Cognitive-behavioral group treatment: description, case presentation, and empirical support. In: Stein MB, editor. Social phobia: clinical and research perspectives. Washington, DC: American Psychiatric Press; 1995.
25. Clark DM, Wells A. A cognitive model of social phobia. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, editors. Social phobia: diagnosis, assessment, and treatment. New York: Guilford Press; 1995.
26. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
27. Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The Liebowitz Social Anxiety Scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther 2002;40:701-715.
28. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D. The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 2001;31: 1025-1035.
29. Levin JB, Marom S, Gur S, Wechter D, Hermesh H. Psychometric properties and three proposed subscales of a self- report version of the Liebowitz Social Anxiety Scale translated into Hebrew. Depress Anxiety 2002;16:143-151.
30. Sheehan D. The anxiety disease. New York: Scribner; 1983.
31. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93-105.
32. Hambrick JP, Turk CL, Heimberg RG, Schneier FR, Liebowitz MR. Psychometric properties of disability measures among patients with social anxiety disorder. J Anxiety Disord 2004; 18:825-839.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville: US Dept of Health, Education and Welfare publication (ADM); 1976:76-338.
34. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 1992;28:425-432.
35. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
36. Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr Scand 1986;74:544-548.
37. Feeny NC, Zoellner LA, Foa EB. Treatment outcome for chronic PTSD among female assault victims with borderline personality characteristics: a preliminary examination. J Personal Disord 2002;16:30-40.
38. Iancu I, Levin J, Hermesh H, Dannon P, Poreh A, Ben-Yehuda Y, Kaplan Z, Marom S, Kotler M. Social phobia symptoms: prevalence, sociodemographic correlates, and overlap with specific phobia symptoms. Compr Psychiatry 2006;47:399-405.
39. Cameron OG, Abelson JL, Young EA. Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function. Biol Psychichiatry 2004; 56:875-883.
40. Von-Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006;26:311-315.
41. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19.
42. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey KS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006;59:1040-1048.
43. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71:1058-1067.
44. Heimberg RG, Horner HR, Juster SA, Safran SA, Brown FR, Liebowitz MR. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212.
45. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J. Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol 2006;74:568-578.
46. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomized controlled trial. Br J Psychiatry 2003;182:312-318.
47. Moscovitch DA, Hofmann SG, Suvak MK, In-Albon T. Mediation of changes in anxiety and depression during treatment of social phobia. J Consult Clin Psychol 2005;73:945-952.
48. Federoff IC, Taylor S. Psychological and pharmacological treatments for social phobia: a meta-analysis. J Clin Psychopharmacol 2001;21:311-324.
49. Feske U, Chambless DL. Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. Behav Ther 1995;26:695-720.
50. Gould RA, Buckminster S, Pollack MH. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 1997;4:291-306.
51. Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM. Cognitive therapy for social phobia: individual versus group therapy. Behav Res Ther 2003;41:991-1007.
52. Mortberg E, Karlsson A, Fyring C, Sundin Ö. Intensive cognitive-behavioral group treatment (CBGT) of social phobia: a randomized controlled study. J Anxiety Disord 2006;20:646-660.
53. Brown TA, Cambell LA, Lehman CL, Grisham GR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 2001;110:49-58.
54. Hook J, Valentiner D. Are specific and generalized social phobias qualitatively distinct? Clin Psychol Sci Pract 2002;9:379-395.
55. Smits JA, Powers MB, Buxkamper R, Telch MJ. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav Res Ther 2006;44:1773-1785.
56. Herbert JD, Gaudiano BA, Rheingold AA, Myers VH, Dalrym- ple K, Nolan EM. Social skills training augments the effectiveness of cognitive behavioral group therapy for social anxiety disorder. Behav Ther 2005;36:125-138.
57. Otto MW, Smiths JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 2004;65(Suppl 5):34-41.
58. Rosser S, Erskine A, Crino R. Pre-existing antidepressants and the outcome of group cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry 2004;38:233-239.
59. Hofmann SG, Suvak M. Treatment attrition during group therapy for social phobia. J Anxiety Disord 2006;20:961-972.
60. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davis S, Holt CS, Goetz D, Juster HR, Lin SH, Bruch MA, Marshall RD, Klein DF. Cognitive-behavioral group therapy versus phenelzine in social phobia: long term outcome. Depress Anxiety 1999;10:89-98.
61. Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Clin Neuropsychopharmacol 2003;6:427-442.
62. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-Week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66:1270-1278.